Europe specialty generics market reached a value of US$ 13.2 Billion in 2018. Specialty generics are classified as high-cost, high complexity and/or high touch generics. They are the generic versions of speciality branded drugs after they lose their patent protection. Specialty generics are used to treat complex diseases which may be chronic by nature and life-threatening like hepatitis C, cancer, rheumatoid arthritis, multiple sclerosis, etc.
Driven by factors such as an increasing aging population, changing lifestyles and a rising prevalence of chronic diseases, healthcare costs in Europe have increased significantly in recent years creating a huge burden on the government, healthcare providers and patients. Specialty generics are playing a major role in the region to reduce this cost burden as they are more cost-effective as compared to their branded versions. Unlike branded speciality drugs, specialty generics don’t require expensive and time-consuming research and development procedures. Additionally, they also don’t incur the same amount of marketing and promotional expenses, resulting in substantially lower costs. In addition to this, the patent expiration of several blockbuster specialty drugs is expected to expire in the coming years creating a positive impact on the market. Looking forward, IMARC Group expects the market value to reach US$ 21.9 Billion by 2024, exhibiting a CAGR of around 9% during 2019-2024.
Historical, Current and Future Market Trends
Market Breakup by Region:
Market Breakup by Route of Administration:
Market Breakup by Indication:
Market Breakup by Distribution Channel:
The leading players in the European specialty generics industry have also been examined in the report.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at